136 related articles for article (PubMed ID: 38763389)
1. Softening the tumor matrix through cholesterol depletion breaks the physical barrier for enhanced antitumor therapy.
Peng Z; Yi Y; Nie Y; Wang T; Tang J; Hong S; Liu Y; Huang W; Sun S; Tan H; Wu M
J Control Release; 2024 Jul; 371():29-42. PubMed ID: 38763389
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
3. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor-associated macrophages to reverse antitumor drug resistance.
Li S; Sheng J; Zhang D; Qin H
Aging (Albany NY); 2024 May; 16(11):10165-10196. PubMed ID: 38787372
[TBL] [Abstract][Full Text] [Related]
5. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
6. Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment.
Ye H; He X; Feng X
Biomed Pharmacother; 2020 Sep; 129():110369. PubMed ID: 32563983
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
[TBL] [Abstract][Full Text] [Related]
8. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
[TBL] [Abstract][Full Text] [Related]
9. A coordinative modular assembly-constructed self-reinforced nano-therapeutic agent for effective antitumor-immune activation.
Zheng Y; Bu F; Xu C; Wu T; Zhou J; Shen W; Yin T
J Control Release; 2024 Jul; 371():588-602. PubMed ID: 38866245
[TBL] [Abstract][Full Text] [Related]
10. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
11. Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.
Liu Y; Wang J; Zhang J; Marbach S; Xu W; Zhu L
ACS Appl Mater Interfaces; 2020 Nov; 12(47):52402-52414. PubMed ID: 33169982
[TBL] [Abstract][Full Text] [Related]
12. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
[TBL] [Abstract][Full Text] [Related]
13. A tumor microenvironment responsive biodegradable CaCO
Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
15. F1 fraction isolated from Mesobuthus eupeus scorpion venom induces macrophage polarization toward M1 phenotype and exerts anti-tumoral effects on the CT26 tumor cell line.
Sadeghi M; Amari A; Asadirad A; Nemati M; Khodadadi A
Int Immunopharmacol; 2024 May; 132():111960. PubMed ID: 38554440
[TBL] [Abstract][Full Text] [Related]
16. BAG3 in Tumor Resistance to Therapy.
De Marco M; Turco MC; Marzullo L
Trends Cancer; 2020 Dec; 6(12):985-988. PubMed ID: 32718905
[TBL] [Abstract][Full Text] [Related]
17. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
[TBL] [Abstract][Full Text] [Related]
18. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
19. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.
Abumanhal-Masarweh H; Koren L; Zinger A; Yaari Z; Krinsky N; Kaneti G; Dahan N; Lupu-Haber Y; Suss-Toby E; Weiss-Messer E; Schlesinger-Laufer M; Shainsky-Roitman J; Schroeder A
J Control Release; 2019 Feb; 296():1-13. PubMed ID: 30615983
[TBL] [Abstract][Full Text] [Related]
20. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
